Orexin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

Authors

  • Paul Coleman Merck Research Laboratories
  • Luis de Lecea Scripps Research Institute
  • Anthony Gotter Merck Research Laboratories
  • Jim Hagan GlaxoSmithKline
  • Rebecca Hills University of Edinburgh
  • Thomas Kilduff SRI International
  • Jyrki P. Kukkonen University of Helsinki https://orcid.org/0000-0002-6989-1564
  • Rod Porter GlaxoSmithKline
  • John Renger Merck Research Laboratories
  • Jerome M Siegel University of California Los Angeles
  • Gregor Sutcliffe Scripps Research Institute
  • Neil Upton GlaxoSmithKline
  • Christopher J. Winrow Merck Research Laboratories

DOI:

https://doi.org/10.2218/gtopdb/F51/2019.4

Abstract

Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [39]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, preproorexin or orexin precursor, by proteolytic cleavage and some typical peptide modifications [102]. Currently the only orexin receptor ligand in clinical use is suvorexant, which is used as a hypnotic. Orexin receptor crystal structures have been solved [124, 123].

Downloads

Published

16-Sep-2019

Issue

Vol. 2019 No. 4 (2019)

Section

Summaries

How to Cite

“Orexin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database” (2019) IUPHAR/BPS Guide to Pharmacology CITE, 2019(4). doi:10.2218/gtopdb/F51/2019.4.